BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26524028)

  • 21. [Clinical Features, Treatment and Prognostic Factors of 94 Patients with Follicular Lymphoma].
    DU XY; Hu K; Zhao W; Yang P; Wan W; Jing HM; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):756-764. PubMed ID: 29950216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review.
    Guan RY; Tang XR; Huang ZF; Du J; Fu XH; Lu G; Mou WW
    Recent Pat Anticancer Drug Discov; 2023 Nov; ():. PubMed ID: 37937574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow].
    Sun Q; Zhang PH; Liu EB; Liu W; Li ZQ; Yang QY; Fang LH; Sun FJ; Chen HS; Qiu LG
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):234-8. PubMed ID: 23928529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
    Wu L; Tian C; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of splenic marginal zone lymphoma.
    Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
    Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma.
    Mollejo M; Lloret E; Solares J; Bergua JM; Mateo M; Piris MA
    Am J Hematol; 1999 Dec; 62(4):242-6. PubMed ID: 10589081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical analysis of 140 cases of mantle cell lymphoma].
    Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
    Bastidas-Mora G; Beà S; Navarro A; Gine E; Costa D; Delgado J; Baumann T; Magnano L; Rivas-Delgado A; Villamor N; Colomer D; Lopez-Guerra M; Rozman M; Balagué O; Martínez D; Baptista MJ; Escoda L; Alcoceba M; Blanes M; Climent F; Campo E; Wotherspoon A; López-Guillermo A; Matutes E
    Br J Haematol; 2022 Jan; 196(1):146-155. PubMed ID: 34519021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of marginal zone lymphoma involving bone marrow.
    Kent SA; Variakojis D; Peterson LC
    Am J Clin Pathol; 2002 May; 117(5):698-708. PubMed ID: 12090417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
    Muntañola A; Villalobos MT; González-Villambrosia S; Rodríguez-Salazar MJ; Jiménez-Ubieto A; Bastidas-Mora G; Córdoba R; Infante M; Vidal MJ; Díaz FJ; Baile M; Bastos-Oreiro M; Panizo C; Sancho JM; Navarro B; García T; Escoda L; Abrisqueta P; Terol MJ; de Campo R; Mozas P; López-Guillermo A; Salar A; Montalbán C;
    Br J Haematol; 2023 Aug; 202(4):776-784. PubMed ID: 37386877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splenic marginal zone lymphomas presenting with splenomegaly and typical immunophenotype are characterized by allelic loss in 7q31-32.
    Boonstra R; Bosga-Bouwer A; van Imhoff GW; Krause V; Palmer M; Coupland RW; Dabbagh L; van den Berg E; van den Berg A; Poppema S
    Mod Pathol; 2003 Dec; 16(12):1210-7. PubMed ID: 14681321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R; Bergamaschini L; Deliliers GL
    Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?
    Ponzoni M; Kanellis G; Pouliou E; Baliakas P; Scarfò L; Ferreri AJ; Doglioni C; Bikos V; Dagklis A; Anagnostopoulos A; Ghia P; Stamatopoulos K; Papadaki T
    Am J Surg Pathol; 2012 Nov; 36(11):1609-18. PubMed ID: 23073320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of blood and bone marrow examination in the diagnosis of mature lymphoid neoplasms in patients presenting with isolated splenomegaly.
    Sreedharanunni S; Sachdeva MU; Malhotra P; Ahluwalia J; Naseem S; Prakash G; Khadwal A; Sharma P; Kumar N; Varma N; Varma S; Das R
    Hematology; 2015 Oct; 20(9):530-7. PubMed ID: 25760312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.
    Arcaini L; Varettoni M; Boveri E; Orlandi E; Rattotti S; Zibellini S; Merli M; Lucioni M; Rizzi S; Gotti M; Morello L; Pascutto C; Paulli M
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):103-5. PubMed ID: 21454204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Splenic marginal zone lymphoma: disease features and management.
    Matutes E
    Expert Rev Hematol; 2013 Dec; 6(6):735-45. PubMed ID: 24168526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement.
    Florena AM; Tripodo C; Porcasi R; Ingrao S; Fadda MR; De Cantis S; Iannitto E; Franco V
    Leuk Lymphoma; 2006 Jan; 47(1):49-57. PubMed ID: 16321827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
    Cervetti G; Galimberti S; Sordi E; Buda G; Orciuolo E; Cecconi N; Petrini M
    Ann Oncol; 2010 Apr; 21(4):851-854. PubMed ID: 19825880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
    Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
    Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features of CD5-positive splenic marginal zone lymphoma.
    Li Y; Wang G; Liu E; Zhang D; Zhang Y; Jian X; Zhao W; Li W
    J Clin Pathol; 2024 May; 77(6):421-425. PubMed ID: 36922019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.